Data completeness
3/8 — Basic
BORTEZOMIB (bortezomib) by Teva is chymotrypsin-like activity of the 26s proteasome in mammalian cells. Approved for multiple myeloma, al amyloidosis, mantle cell lymphoma and 12 more indications.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Bortezomib is a proteasome inhibitor that blocks the chymotrypsin-like activity of the 26S proteasome, preventing degradation of ubiquitinated proteins and disrupting cellular homeostasis to induce cancer cell death. It is indicated across a broad spectrum of hematologic malignancies including multiple myeloma, mantle cell lymphoma, and various leukemias, as well as emerging uses in solid tumors and non-malignant conditions. Administered via injection, bortezomib represents a foundational mechanism in oncology with multi-indication potential.
Pre-Launch
As a pre-launch asset, bortezomib represents a greenfield opportunity for commercial teams to establish brand positioning and build infrastructure across multiple oncology indications.
Mechanism of Action
chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining…
Worked on BORTEZOMIB at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.